Q2 2026 · Form 13F Ledger数据来源:SEC EDGAR  
H

HOLDER.TOP

谁持有什么——美股机构持仓的季度账本。
EN · 简 · 繁
机构 / Soleus Capital Management, L.P.
Form 13F · Q2 2026

Soleus Capital Management, L.P.

CIK 1802630申报日 2026-08-1113F-HR 在 EDGAR 查看原始申报 ↗
$29.0亿
申报组合市值
97
持仓数量
12
Quarters on record
Top 50
持仓数量

Soleus Capital Management, L.P.——持仓

共 97 个持仓中的前 50 名,按申报市值排名。股数变动与上一季度对比。
#证券股数股数环比市值占其组合
1KRYS Krystal Biotech Inc939,254−18.5%$3.5亿12.0%
2CELC Celcuity Inc1.7M+32.7%$1.8亿6.1%
3TGTX Tg Therapeutics Inc2.9M−27.3%$1.6亿5.5%
4PODD Insulet Corp1.0M+86.5%$1.6亿5.5%
5NVCR Novocure Ltd9.9M−5.5%$1.5亿5.2%
6UTHR United Therapeutics Corp Del225,587+20.5%$1.2亿4.2%
7INSP Inspire Med Sys Inc1.9M+235.1%$8616万3.0%
8RIGL Rigel Pharmaceuticals Inc1.8M+18335.0%$7212万2.5%
9ANIP Ani Pharmaceuticals Inc867,760+5.8%$7183万2.5%
10BBNX Beta Bionics Inc4.4M+0.9%$6885万2.4%
11VCEL Vericel Corp1.5M−42.8%$6492万2.2%
12PRAX Praxis Precision Medicines I177,517−46.3%$5943万2.0%
13GERN Geron Corp42.8M+3.1%$5480万1.9%
14ALKS Alkermes Plc1.0M−47.8%$5393万1.9%
15ERAS Erasca Inc2.7M—$4946万1.7%
16NPCE Neuropace Inc2.9M−0.7%$4626万1.6%
17PGNY Progyny Inc1.6M−22.5%$4619万1.6%
18INDIVIOR PHARMACEUTICALS INC Indivior Pharmaceuticals Inc1.1M−16.5%$4366万1.5%
19PBLS Parabilis Medicines Inc1.5M—$4010万1.4%
20FOCL Edap Tms S A7.3M+0.0%$3786万1.3%
21GMED Globus Med Inc468,922−35.7%$3705万1.3%
22RCUS Arcus Biosciences Inc1.2M+158.6%$3603万1.2%
23SNDX Syndax Pharmaceuticals Inc1.6M−5.7%$3559万1.2%
24NRIX Nurix Therapeutics Inc1.5M+56.2%$3554万1.2%
25LEGN Legend Biotech Corp1.2M—$3480万1.2%
26JBIO Jade Biosciences Inc1.6M+94.6%$3446万1.2%
27UNH Unitedhealth Group Inc80,000—$3325万1.1%
28AVTX Avalo Therapeutics Inc1.7M+274.4%$3058万1.1%
29URGN Urogen Pharma Ltd829,810+14.1%$3054万1.1%
30MBX Mbx Biosciences Inc515,279+188.0%$2844万1.0%
31PALI Palisade Bio Inc13.1M—$2730万0.9%
32PHVS Pharvaris N V730,907+4.1%$2527万0.9%
33ORGO Organogenesis Hldgs Inc10.1M+0.5%$2464万0.8%
34SUPN Supernus Pharmaceuticals520,000—$2419万0.8%
35PRCT Procept Biorobotics Corp1.0M+526.9%$2265万0.8%
36TNGX Tango Therapeutics Inc709,000+57.6%$2216万0.8%
37IKT Inhibikase Therapeutics Inc10.9M+0.0%$2208万0.8%
38TRVI Trevi Therapeutics Inc1.2M−27.2%$2200万0.8%
39BMRN Biomarin Pharmaceutical Inc375,572−42.3%$2149万0.7%
40LIVN Livanova Plc254,957−56.2%$2097万0.7%
41ARGX Argenx Se19,955+470.1%$1851万0.6%
42NVCT Nuvectis Pharma Inc1.0M—$1839万0.6%
43CAPR Capricor Therapeutics Inc761,737—$1834万0.6%
44EWTX Edgewise Therapeutics Inc450,889−68.9%$1832万0.6%
45PRLD Prelude Therapeutics Inc3.4M—$1801万0.6%
46XENE Xenon Pharmaceuticals Inc267,000−8.6%$1612万0.6%
47CCCC C4 Therapeutics Inc3.4M−11.2%$1578万0.5%
48KNSA Kiniksa Pharmaceuticals Intl246,353−52.7%$1575万0.5%
49KIDS Orthopediatrics Corp732,144+19.0%$1401万0.5%
50AVLN Avalyn Pharmaceuticals Inc419,000—$1379万0.5%
来源:经 SEC EDGAR 的 Form 13F 申报。持仓截至 2026 年 6 月 30 日。期权(看涨/看跌)不计入股数。